Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $35.25.

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. HC Wainwright lowered their target price on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a report on Monday, December 16th. JMP Securities cut their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st.

Insider Buying and Selling

In other news, CEO Kevin Lee sold 3,212 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the sale, the chief executive officer now owns 380,864 shares of the company’s stock, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Bros. Advisors Lp Baker purchased 985,397 shares of the stock in a transaction dated Friday, December 13th. The shares were acquired at an average price of $13.76 per share, for a total transaction of $13,559,062.72. Following the acquisition, the director now directly owns 9,537,643 shares of the company’s stock, valued at $131,237,967.68. This represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 10,840 shares of company stock valued at $259,128. 8.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of large investors have recently made changes to their positions in BCYC. Assetmark Inc. purchased a new position in Bicycle Therapeutics during the third quarter valued at approximately $34,000. GAMMA Investing LLC boosted its stake in shares of Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after buying an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after acquiring an additional 2,918 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Bicycle Therapeutics in the second quarter worth $206,000. Finally, Crossmark Global Holdings Inc. purchased a new stake in shares of Bicycle Therapeutics during the third quarter worth $257,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $14.68 on Monday. Bicycle Therapeutics has a one year low of $12.17 and a one year high of $28.67. The stock’s fifty day moving average is $21.83 and its 200-day moving average is $22.50. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -4.46 and a beta of 0.86.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. The firm had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s quarterly revenue was down 50.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.26) EPS. Analysts forecast that Bicycle Therapeutics will post -3.05 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.